Stockscreener 앱 받기
323.86
0.24%
-0.79
시장 영업 전:
323.86
전일 마감가:
$324.65
열려 있는:
$325.05
하루 거래량:
440.08K
Relative Volume:
0.67
시가총액:
$12.74B
수익:
$1.40B
순이익/손실:
$177.69M
주가수익비율:
71.60
EPS:
4.5234
순현금흐름:
$174.93M
1주 성능:
-0.65%
1개월 성능:
-1.97%
6개월 성능:
+43.59%
1년 성능:
+10.48%
1일 변동 폭
$323.86
$325.05
1주일 범위
$323.71
$327.44
52주 변동 폭
$221.26
$362.41
Penumbra Inc Stock (PEN) Company Profile
명칭
Penumbra Inc
전화
(510) 995-2486
주소
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
323.86 | 12.74B | 1.40B | 177.69M | 174.93M | 4.5234 |
ABT
Abbott Laboratories
|
87.17 | 151.83B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
295.25 | 113.08B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
77.79 | 99.87B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
55.98 | 83.21B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.91 | 47.80B | 6.30B | 1.07B | 1.34B | 1.8406 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-12-11 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-11-18 | 개시 | Wells Fargo | Underweight |
| 2025-10-08 | 업그레이드 | Needham | Hold → Buy |
| 2025-09-02 | 개시 | Evercore ISI | Outperform |
| 2025-03-14 | 개시 | BofA Securities | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-12-17 | 개시 | Oppenheimer | Outperform |
| 2024-12-11 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-09-18 | 개시 | Stifel | Buy |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-31 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-07-31 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-02-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-09-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-07-19 | 개시 | Robert W. Baird | Outperform |
| 2023-03-29 | 다운그레이드 | Needham | Buy → Hold |
| 2023-01-30 | 개시 | Piper Sandler | Overweight |
| 2022-11-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-05 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-09-09 | 업그레이드 | Needham | Hold → Buy |
| 2022-07-18 | 개시 | RBC Capital Mkts | Outperform |
| 2022-04-19 | 개시 | Deutsche Bank | Buy |
| 2022-03-08 | 개시 | Needham | Hold |
| 2021-09-16 | 개시 | Truist | Buy |
| 2021-06-04 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-12-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-10-07 | 재개 | Canaccord Genuity | Buy |
| 2020-09-29 | 개시 | BTIG Research | Buy |
| 2020-09-08 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-05-30 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-05-21 | 개시 | William Blair | Outperform |
| 2018-10-29 | 재개 | BofA/Merrill | Buy |
| 2018-10-08 | 개시 | RBC Capital Mkts | Outperform |
| 2018-02-21 | 개시 | William Blair | Outperform |
| 2018-01-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-11-30 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-13 | 개시 | Wells Fargo | Outperform |
모두보기
Penumbra Inc 주식(PEN)의 최신 뉴스
Penumbra earnings in focus as Boston Scientific deal looms - Investing.com
MSN Money - MSN
Vanguard Group Inc. Cuts Stock Position in Penumbra, Inc. $PEN - MarketBeat
Inside Boston Scientific's $15 billion offer for Alameda's largest employer - The Business Journals
PEN Stock Price, Quote & Chart | PENUMBRA INC (NYSE:PEN) - ChartMill
Penumbra, Inc. (NYSE:PEN) Sees Large Drop in Short Interest - MarketBeat
Vanguard Capital Management (NYSE: PEN) holds 1.99M shares, 5.07% stake - Stock Titan
[ARS] Penumbra Inc SEC Filing - Stock Titan
Penumbra (PEN) down 1.6% since last earnings report: Can it rebound? - MSN
Penumbra (NYSE: PEN) outlines 2026 meeting and $14.5B Boston Scientific sale - Stock Titan
Teacher Retirement System of Texas Reduces Stake in Penumbra, Inc. $PEN - MarketBeat
3 Reasons Why Penumbra (PEN) Is a Great Growth Stock - Yahoo Finance
Investor Outlook: Penumbra, Inc. (PEN) Eyes 10.88% Upside With Strong Revenue Growth - DirectorsTalk Interviews
Why (PEN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
How STORM-PE Thrombectomy Results and Lightning Flash Data Will Impact Penumbra (PEN) Investors - simplywall.st
Penumbra Deadline Alert - TMX Newsfile
Q3 2025 Penumbra Inc Earnings Call Transcript - GuruFocus
Penumbra Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
M&T Bank Corp Grows Position in Penumbra, Inc. $PEN - MarketBeat
Penumbra names Shruthi Narayan as president, effective September 1 - MSN
Penumbra (PEN) urges shareholders to approve Boston Scientific merger May 6 - Stock Titan
Boston Scientific to acquire Penumbra for enterprise value of ~$14.5B - MSN
Penumbra (PEN) Deep Dive | Q4 2025: Profit Exceeds ViewsNCAV - Xã Thanh Hà
Penumbra vote May 7 as Boston Scientific (NYSE: PEN) aims H2 2026 close - Stock Titan
Neurovascular Microcatheter Market Is Going to Boom Rapidly | Medtronic, Penumbra, Stryker - openPR.com
Penumbra, Inc. (PEN) Stock Analysis: A Healthcare Contender With 10% Upside Potential - DirectorsTalk Interviews
Penumbra Inc stock (US70975L1070): Why Google Discover changes matter more now - AD HOC NEWS
Penumbra (PEN) Stock: Why Strong Balance Sheet (Momentum Building) 2026-04-18Rating Change - Cổng thông tin điện tử Tỉnh Sơn La
Form 425Prospectuses and communications, business combinations - ADVFN
FTC Issues Second Request for Boston Scientific and Penumbra Merger - HarianBasis.co
Penumbra Inc (NYSE:PEN) Presents a Compelling Growth and Breakout Opportunity - ChartMill
Board backs Boston Scientific acquisition of Penumbra (PEN); Special Meeting May 6, 2026 - Stock Titan
Penumbra, Inc. (NYSE:PEN) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Did STORM-PE’s Strong Functional Outcomes Just Shift Penumbra's (PEN) Investment Narrative? - Sahm
Understanding Momentum Shifts in (PEN) - Stock Traders Daily
Boston Scientific’s $14.9 Billion Bet: The Strategic "Homecoming" to Neurovascular Dominance - FinancialContent
Consolidation Fever: Boston Scientific’s $14.9 Billion Bet on Penumbra Signals New Era in MedTech M&A - The Chronicle-Journal
Here's Why Penumbra (PEN) is a Strong Growth Stock - Yahoo Finance
A Look At Boston Scientific (BSX) Valuation After The Penumbra Acquisition And Recent Shareholder Returns - Yahoo Finance
Penumbra (PEN) to Release Quarterly Earnings on Wednesday - MarketBeat
RBC Capital Maintains Penumbra(PEN.US) With Hold Rating, Maintains Target Price $374 - Moomoo
Penumbra Inc stock (US70975L1070): Why its neurovascular leadership matters more now for investors - AD HOC NEWS
Penumbra Presents STORM-PE 90-day Results at SIR - dicardiology.com
Penumbra trial shows improved outcomes for pulmonary embolism By Investing.com - Investing.com Australia
Study backs Penumbra computer-assisted thrombectomy - MassDevice
Penumbra (PEN) Reports Positive Outcomes from STORM-PE Trial - GuruFocus
Aug PreEarnings: What is the long term forecast for Penumbra Inc stock2026 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Penumbra Inc (PEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.41%
0.93%
자본화:
|
볼륨(24시간):